参考文献/References:
[1] Kralev S,Schneider K,Lang S,et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography[J]. PLoS One,2011,6(9):e24964.
[2] 周胜华. 心房颤动 (7)冠心病合并心房颤动的治疗(续完)[J]. 中国循环杂志,2013,28(5):327-329.
[3] Steensig K,Olesen KKW,Thim T,et al. CAD is an independent risk factor for stroke among patients with atrial fibrillation[J]. J Am Coll Cardiol,2018,72(20):2540-2542.
[4] Choi HI,Ahn JM,Kang SH,et al. Prevalence,management,and long-term(6-year) outcomes of atrial fibrillation among patients receiving drug-eluting coronary stents[J]. JACC Cardiovasc Interv,2017,10(11):1075-1085.
[5] van Rein N,Heide-Jorgensen U,Lijfering WM,et al. Major bleeding rates in atrial fibrillation patients on s ingle,dual,or triple antithrombotic therapy[J]. Circulation,2019,139(6):775-786.
[6] 吴双,杨艳敏. 心房颤动合并急性冠状动脉综合征的抗血栓治疗进展[J]. 心血管病学进展,2017,38(5):499-502.
[7] Lamberts M,Gislason GH,Lip GY,et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant:a nationwide cohort study[J]. Circulation,2014,129(15):1577-1585.
[8] Fischer Q,Georges JL,le Feuvre C,et al. Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation:“OLTAT registry”[J]. Int J Cardiol,2018,264:64-69.
[9] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS)[J]. Eur Heart J,2021,42(5):373-498.
[10] Hurlen M,Abdelnoor M,Smith P,et al. Warfarin,aspirin,or both after myocardial infarction[J]. N Engl J Med,2002,347(13):969-974.
[11] van Es RF,Jonker JJ,Verheugt FW,et al. Aspirin and coumadin after acute coronary syndromes(the ASPECT-2 study):a randomised controlled trial[J]. Lancet,2002,360(9327):109-113.
[12] Eikelboom JW,Connolly SJ,Bosch J,et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med,2017,377(14):1319-1330.
[13] Lemesle G,Ducrocq G,Elbez Y,et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation:association with ischemic and bleeding events[J]. Clin Cardiol,2017,40(10):932-939.
[14] Hamon M,Lemesle G,Tricot O,et al. Incidence,source,determinants,and prognostic impact of major bleeding in outpatients with stable coronary artery disease[J]. J Am Coll Cardiol,2014,64(14):1430-1436.
[15] Patti G,Pecen L,Lucerna M,et al. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy—A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries[J]. Int J Cardiol,2018,270:160-166.
[16] Matsumura-Nakano Y,Shizuta S,Komasa A,et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation[J]. Circulation,2019,139(5):604-616.
[17] Yasuda S,Kaikita K,Akao M,et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease[J]. N Engl J Med,2019,381(12):1103-1113.
[18] Seivani Y,Abdel-Wahab M,Geist V,et al. Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents[J]. Clin Res Cardiol,2013,102(11):799-806.
[19] Knuuti J,Wijns W,Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J,2020,41(3):407-477.
[20] Steffel J,Collins R,Antz M,et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Europace,2021,23(10):1612-1676.
[21] Angiolillo DJ,Bhatt DL,Cannon CP,et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention:A North American Perspective:2021 Update[J]. Circulation,2021,143(6):583-596.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(1):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(1):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(1):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(1):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]